Skip to main content

Home/ Medicine & Healthcare/ Group items tagged recurrence-rate

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod ... - 0 views

www.mendeley.com/...gterm-followup-study-in-europe

imiquimod aldara recurrence recurrence-rate recurrences pubs pubmed 5-year long-term follow-up treatment conclusion cream study

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. by Harald Gollnick
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2008 Nov-Dec] - ... - 0 views

www.ncbi.nlm.nih.gov/...18955210

imiquimod aldara recurrence recurrence-rate 5-year pubmed pubs recurrences

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The estimate of overall treatment success for all treated patients at the end of follow-up was 77.9% (80.9% considering histology). The data support clinical assessment of initial response as predictive of long-term outcome. Most of the recurrences occurred early, indicating that careful follow-up is important during the first year after treatment.
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinoma following successful treatment with... - 0 views

www.jle.com/...article.phtml

recurrence rate recurrences recurrence-rate BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies free fulltext free

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%. 
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2005 Sep-Oct] - ... - 0 views

www.ncbi.nlm.nih.gov/...16172048

recurrence rate recurrences recurrence-rate BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%.
avivajazz jazzaviva

Nonsurgical Treatment Options for Basal Cell Carcinoma | Review Article | Journal of Sk... - 0 views

www.hindawi.com/...571734

BCC sBCC studies pubs outcomes efficacy therapy therapies treatment options treatments

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Journal of Skin CancerVolume 2011 (2011), Article ID 571734, 6 pagesdoi:10.1155/2011/571734 © 2011 Mary H. Lien and Vernon K. Sondak.
avivajazz jazzaviva

Two-year interim results from a 5-year study evaluating clinical recurrence o... - 0 views

onlinelibrary.wiley.com/...abstract

BCC sBCC studies pubs outcomes efficacy therapy therapies results study clinical cream treatment

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5×/week dosing yield similar clearance rates, but daily dosing increases local skin reactions.
avivajazz jazzaviva

Has imiquimod 5% cream a role in the management of... [Eur J Dermatol. 2009 Sep-Oct] - ... - 0 views

www.ncbi.nlm.nih.gov/...19527989

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies recurrent refractory 3-year followup

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.
avivajazz jazzaviva

Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: A 3-year re... - 0 views

www.sbd-sp.org.br/...destaque04.pdf

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies PDF

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    PDF, Free full text article... We found that 5% imiquimod cream is aneffective treatment option for superficial and nodularbasal cell carcinomas, giving a clearance rate of89.5% at an average of 39 months of follow up.   Dr Yin Vun, Siller Medical, 9th Floor, SilvertonPlace, 101 Wickham Terrace, Brisbane, Qld 4000, Australia.
avivajazz jazzaviva

Two-year interim results from a 5-year study evalu... [Australas J Dermatol. 2006] - Pu... - 0 views

www.ncbi.nlm.nih.gov/...17034468

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies 5-year results

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5x/week dosing yield similar clearance rates, but daily dosing increases local skin reactions.
avivajazz jazzaviva

Management of superficial basal cell carcinoma: fo... [Clin Cosmet Investig Dermatol. 2... - 0 views

www.ncbi.nlm.nih.gov/...21436969

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    To date one long-term study indicates a treatment success rate of 78%-81% and that initial response is a predictor of long-term outcome. Recurrences tend to occur within the first year after treatment. Future research will compare this preparation to the gold standard treatment for superficial BCC - surgical excision.
1 - 10 of 10
Showing 20▼ items per page